All News

RheumNow Podcast square

Sniffles & Arthritis (3.1.2024)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com. Are these associations with infection, biomarkers and weather real or imaginary? Linked or luck? Causal or casual?  You decide....

Read Article
PSA068.jpg

Many with Psoriatic Arthritis Fail to Achieve Minimal Disease Activity

Jack Cush, MD

Despite the availability of numerous advanced therapies for psoriatic arthritis (PsA), there remains a substantial burden and unmet need for improved therapies, according to a newly published Canadian study.

Read Article
RheumNow Podcast square

Immunosuppression Increasing (2.23.2024)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal reports from the past 2 weeks on RheumNow.com; but begins with a discussion of what constitutes "immunosuppression" and how it applies to our patients.

Read Article
Winthrop RNL

Five Takeaways in PsA/SpA at RNL 2024

Rachel Tate, DO

Continuing with the theme of clinical pearls, the PsA and SpA speakers also provided a wealth of information. Here are my five key takeaways and clinical pearls. 

Read Article
Dr. Eder at RNL

Sex Disparities in PsA/SpA

Kathryn H. Dao, M.D.

Dr. Eder delivered an illuminating talk at RheumNow Live 2024 on sex differences in psoriatic arthritis; the disease may manifest differently in men and women, and therapeutic responses may differ between the sexes.

Read Article
April Armstrong RNL

Co-management of Psoriatic Disease

Richard Conway, MBBChBAO, PhD

It is a common clinical scenario to see someone with both severe psoriatic arthritis and skin psoriasis. In an ideal world this would involve a combined clinic with our local friendly dermatologist. For many of us, however, this is not practical for many reasons. The excellent Saturday morning session on choosing systemic therapies in psoriatic disease at RheumNow Live 2024 from dermatologist extraordinaire Dr. April Armstrong was therefore hugely insightful.

Read Article
Many with PsA Fail to Achieve Minimal Disease Activity Despite the availability of numerous advanced therapies for PsA, there remains a substantial burden and unmet need for improved therapies, according to a newly published Canadian study https://t.co/OUb3bKo98v https://t.co/FDCBcdyIBm

Links:

Dr. John Cush RheumNow ( View Tweet)
Feb 2024 EMA meeting approved biosimilar ustekinumab (Pyzchiva) for adult/pediatric psoriasis; psoriatic arthritis; UC/Crohn's. & also approved generic Apremilast Accordfor the treatment of psoriatic arthritis, psoriasis, and Behçet disease https://t.co/Cu9f4qQjgP https://t.co/qmH3ZkfReN

Links:

Dr. John Cush RheumNow ( View Tweet)
How do you manage enthesitis? Enthesitis can be a challenge for clinicians to identify, evaluate, and manage in patients with psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA). https://t.co/BlC3onBYSX https://t.co/OXPdZuJHaN

Links:

Dr. John Cush RheumNow ( View Tweet)
Five Takeaways in PsA/SpA at RNL 2024 Continuing with the theme of clinical pearls, the PsA and SpA speakers also provided a wealth of information. Click the link to read our five key takeaways and clinical pearls. https://t.co/ekKUl5WelF https://t.co/IdPXd7LR65

Links:

Dr. John Cush RheumNow ( View Tweet)
Orismilast is a novel oral phosphodiesterase-4 (PDE4) B/D inhibitor studied in phase 2b RCT in 202 moderate-to-severe psoriasis pts vs PBO. At wk 16, Orismilast was better at PASI 75 (40%-49% vs PBO 16.5%; P <.05) and PASI90 (22%-28% vs 8%; P <.05) https://t.co/wSmiO2Hr5W https://t.co/gMiQUfT6EG

Links:

Dr. John Cush RheumNow ( View Tweet)
Oral IL-23 Inhibitor Effective in Psoriasis The NEJM has published the results of the FRONTIER 1 trial demonstrating the efficacy of JNJ-77242113, an oral interleukin-23 (IL-23) receptor antagonist peptide, in patients with psoriasis (PSO). https://t.co/NRK8LnM5zp https://t.co/FnWEze976O

Links:

Dr. John Cush RheumNow ( View Tweet)
Retrospective cohort analysis of 330 psoriasis pts - 83 (25%) developed #PsA after mean of 36 (3.5–114) mos. PsA Predictive factors include being female (OR=3.33), nails involved (OR=5.4), severe PSO (OR=27.4), po systemic Rx prior to PsA (4.1) https://t.co/w2OO0t3PtR https://t.co/0oh5fDqVhJ

Links:

Dr. John Cush RheumNow ( View Tweet)
Ixekizumab Safety from 25 RCTs (17 PsO, 4 PsA, 4 axSpA) w/ 9225 pts (22371 PYs use). Long-term safety c/w earlier reports/PI. SAEs in 1204 (13%); 45 deaths); ISRs 5.9-11.6/100PYs; IBD ≤ 0.8/100PY; depression, CVA, Cancer : ≤ 1.6/100PY https://t.co/p7N6ZMVvqh https://t.co/22WYkevhaf

Links:

Dr. John Cush RheumNow ( View Tweet)
Current PsA treatment options. A review with @RWCSmtg @JointMD #RWCS24 @RheumNow https://t.co/9I0TfyILvQ

Links:

Dr. Rachel Tate uptoTate ( View Tweet)
Controversial MOSAIC results. @JointMD and @RWCSmtg discuss nuances listed below. #RWCS24 @RheumNow https://t.co/aVRJpqHuUM

Links:

Dr. Rachel Tate uptoTate ( View Tweet)
Sex Disparities in PsA/SpA https://t.co/3pmFyo6Ztm https://t.co/zanPiI7GT5

Links:

Dr. John Cush RheumNow ( View Tweet)
Obesity increase risk of psoriasis Obesity increase risk of PsA in psoriasis pts RWCS24 https://t.co/Wt9h0QLbKH
Dr. John Cush RheumNow ( View Tweet)
Co-management of Psoriatic Disease It is a common clinical scenario to see someone with both severe psoriatic arthritis and skin psoriasis. Co-management with dermatology optimises the care of this patient group. https://t.co/8xZ9ZBpa3O https://t.co/xMYLhxA1j1

Links:

Dr. John Cush RheumNow ( View Tweet)
Racial and Ethnic Determinants of Psoriatic Arthritis A study from a large metropolitan registry of psoriatic arthritis (PsA) patients showed several racial and/or ethnic groups are underrepresented and demonstrate differences in disease activity. https://t.co/uJD5DWZEwM https://t.co/5dg0ubQzvL

Links:

Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×